EPM

Company Overview

Snapshot

Founded in October 2017 by Reshef Swisa, EPM operates with 1–10 employees. The company has raised $2.5M across four funding rounds from four investors. In November 2021, EPM secured a convertible debt funding round.

Business overview

EPM develops prescription medicine utilizing synthetic cannabinoid acids to address unmet patient needs, focusing on therapeutic conditions such as metabolic disorders (Prader-Willi syndrome) and inflammatory skin disease (psoriasis). The company has established a pipeline that includes 14 protected synthetic molecules, with eight novel structures, alongside proprietary production process intellectual property. EPM operates within the Health Tech & Life Sciences sector, specifically in Pharmaceuticals, and is currently in the clinical trial stage for its products.

Strategic signal

In April 2022, the Securities Authority halted EPM's public offering, indicating regulatory scrutiny over the company's fundraising methods. This event signals potential challenges in EPM's path to public markets and highlights the importance of regulatory compliance in the pharmaceutical and biotech sectors, which could impact investor confidence and future capital-raising strategies.

Company Intelligence Q&A

What is EPM's primary focus in drug development?

EPM focuses on developing prescription medicine derived from synthetic cannabinoid acids, targeting metabolic disorders like Prader-Willi syndrome and inflammatory skin diseases such as psoriasis.

When was EPM founded and by whom?

EPM was founded in October 2017 by Reshef Swisa.

What was a significant regulatory event for EPM in 2022?

In April 2022, the Securities Authority halted EPM's offering via television, as reported by Globes.